Is Eiko Lifescience overvalued or undervalued?
As of June 27, 2025, Eiko Lifescience is considered overvalued with a PE Ratio of 46.97 and an EV to EBITDA of 35.01, significantly higher than its peers, and has declined 19.13% year-to-date compared to a 7.58% gain in the Sensex.
As of 27 June 2025, the valuation grade for Eiko Lifescience has moved from fair to expensive, indicating that the company is overvalued. The key ratios reflect this assessment, with a PE Ratio of 46.97, an EV to EBITDA of 35.01, and a PEG Ratio of 0.70. These figures suggest that the stock is trading at a premium compared to its earnings growth potential.In comparison to its peers, Eiko Lifescience's valuation stands out as significantly higher; for instance, Life Insurance has a PE Ratio of 12.53 and EV to EBITDA of 9.88, both indicating a more attractive valuation. Additionally, Bajaj Finserv, categorized as expensive, has a PE Ratio of 36.79, which is still markedly lower than Eiko's. The recent performance of Eiko Lifescience shows a year-to-date decline of 19.13%, contrasting with a 7.58% gain in the Sensex, further supporting the notion that the stock is overvalued.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
